Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | PSB205 |
Trade Name | |
Synonyms | PSB-205|PSB 205|QL-1706|QL 1706|QL1706 |
Drug Descriptions |
PSB205 comprises the combination of a monoclonal antibody targeting CD274 (PD-L1) and a monoclonal antibody CTLA4, which has potential anti-tumor activity (J Clin Oncol 40, 2022 (suppl 16; abstr 2611)). |
DrugClasses | CTLA4 Antibody 31 PD-L1/PD-1 antibody 121 |
CAS Registry Number | NA |
NCIT ID | C162774 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Bevacizumab + Carboplatin + Pemetrexed Disodium + PSB205 | Bevacizumab Carboplatin PSB205 Pemetrexed Disodium | 0 | 0 |
Carboplatin + Paclitaxel + PSB205 | Carboplatin PSB205 Paclitaxel | 0 | 0 |
Carboplatin + Pemetrexed Disodium + PSB205 | Carboplatin PSB205 Pemetrexed Disodium | 0 | 0 |
PSB205 | PSB205 | 0 | 1 |